- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00509002
Iressa Study in Patients With Salivary Gland Cancer
Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)
Study Overview
Detailed Description
Epidermal growth factor receptor (EGFR) may be involved in certain types of cancer, including squamous cell carcinoma of the skin. When EGFR is stimulated, a series of chemical reactions starts that results in a tumor being "told" to grow. ZD1839 (Iressa® or Gefitinib) tries to stop these reactions by blocking EGFR. This may stop tumors from growing.
If you are eligible to take part in this study, you will take gefitinib treatment by mouth once a day, every day, at about the same time in the morning. It can be taken with or without food. If you forget to take a dose, the last missed dose should be taken as soon as you remember, as long as it is at least 12 hours before the next dose is due to be taken.
Every four weeks during treatment, you will have a physical exam and blood (around 3-4 teaspoons) will be collected for routine tests. If you have skin lesions, the lesions will be measured and photographed for research purposes. You cannot be identified from the pictures. You will also be asked about any side effects you may be experiencing. If your doctor feels it is necessary, you may have more frequent check-ups.
Every eight weeks during treatment, you will have imaging tests. The imaging tests include, a chest x-ray and a CT scan or MRI of the head and neck area. You may also have CT scans of other areas of the body. These tests are being done to check on the status of the disease.
You will continue to take gefitinib as long as the disease is responding to treatment. If at any time during the study the disease becomes worse or you experience any intolerable side effects, you will be taken off the study and your doctor will discuss other treatment options with you.
Sometimes, new information becomes available that may influence your decision to continue in the study. The following new information is available:
Results from two large studies showed that there was no benefit from adding gefitinib to chemotherapy with platinum and one other chemotherapy drug when given as the first treatment for non-small cell lung cancer (NSCLC). Therefore, gefitinib is not approved for use in combination with chemotherapy in the treatment of NSCLC.
This is an investigational study. The FDA has authorized gefitinib for use in cancer research. Up to 80 patients will take part in this study. All will be enrolled at M. D. Anderson.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed salivary gland carcinoma.
- Patients with advanced or recurrent salivary gland cancer who are not candidates for curative surgery or radiotherapy.
- Measurable disease per the RECIST criteria. For disease occurring in previously irradiated field, there must be confirmed progression prior to the date registration and more than three months after completion of radiotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Prior central nervous system (CNS) involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment.
- At least a 2-week recovery from prior therapy toxicity.
- Provision of written informed consent.
- Childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (IUD, birth control pills, or barrier device) during and for 3 months after completion of trial therapy.
Exclusion Criteria:
- Known severe hypersensitivity to or any of the excipients of this product.
- Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma, squamous cell carcinoma of the skin, or cervical cancer in situ.
- Concomitant use of phenytoin, carbamazepine, rifampicin, phenobarbital, or St John's Wort or CYP3A4 (e.g. itraconazole, ketoconazole)
- Treatment with a investigational drug within 28 days before Day 1 of trial treatment.
- Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy (except alopecia)
- Incomplete healing from previous surgery.
- Serum creatinine level greater than CTC grade 2.
- Women who are pregnant or breast feeding.
- Prior or other EGFR inhibiting agents.
- Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
- Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
- Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases.
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.
- Uncontrolled seizure disorder, active neurological disease, or greater than Grade 2 neuropathy.
- Keratoconjunctivitis sicca or incompletely treated eye infection.
- Abnormal marrow function as defined as absolute neutrophil count <1,500/ul or platelets <100,000/ul.
- Second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 3 years previously with no evidence of recurrence; prior low grade [Gleason score less than 6] localized prostate cancer is allowed).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adenoid Cystic Salivary Gland Carcinoma Group
Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
|
250 mg by mouth once a day, every day, at about same time in morning.
Other Names:
|
Experimental: Other Carcinoma of Salivary Gland Group
Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
|
250 mg by mouth once a day, every day, at about same time in morning.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy
Time Frame: Every 4 weeks until progressive disease, unacceptable toxicity or patient withdrawal
|
The modified Response Evaluation Criteria in Solid tumors (RECIST) criteria was used for objective tumor response assessment.
Complete Response (CR): Disappearance all target lesions; Partial Response (PR): >30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): >20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or > new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started.
Response rate estimated by Gehan's Phase II clinical trial design.
|
Every 4 weeks until progressive disease, unacceptable toxicity or patient withdrawal
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: George Blumenschein, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004-0089
- NCI-2010-00744 (Registry Identifier: NCI CTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Salivary Gland Cancer
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland CancerUnited States
-
University of Michigan Rogel Cancer CenterAscentage Pharma Group Inc.SuspendedSalivary Gland Cancer | Malignant Salivary Gland CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer | High-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell Tumor | Salivary Gland Adenocarcinoma | Salivary Gland Poorly Differentiated CarcinomaUnited States
-
Samsung Medical CenterActive, not recruitingSalivary Gland CancerKorea, Republic of
-
Peking Union Medical CollegeNot yet recruiting
-
University of WashingtonCompletedMetastatic Malignant Neoplasm in the Bone | Salivary Gland Carcinoma | Metastatic Malignant Neoplasm in the Lung | Stage IV Major Salivary Gland Cancer AJCC v8 | Stage IVA Major Salivary Gland Cancer AJCC v8 | Stage IVB Major Salivary Gland Cancer AJCC v8 | Stage IVC Major Salivary Gland Cancer...United States
-
Clinical Center of VojvodinaCompletedSalivary Gland Neoplasms | Salivary Gland CancerSerbia
-
Peking UniversityUnknown
-
NRG OncologyNational Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland CarcinomaUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Completed
Clinical Trials on Gefitinib
-
Sun Yat-sen UniversityUnknown
-
Qilu Pharmaceutical Co., Ltd.UnknownNon-small-cell Lung CancerChina
-
Sun Yat-sen UniversityWu Jieping Medical FoundationCompletedNon-small Cell Lung CancerChina
-
Jiangsu Famous Medical Technology Co., Ltd.UnknownNon-small Cell Lung Cancer
-
AstraZenecaCompletedNeoplasms, Squamous CellUnited States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
-
Anhui Medical UniversityUnknownSelf Efficacy | Drug ToxicityChina
-
NCIC Clinical Trials GroupCompletedProstate CancerCanada
-
University of Maryland, BaltimoreNational Cancer Institute (NCI); University of Maryland Greenebaum Cancer CenterCompleted
-
Samsung Medical CenterUnknownNon-small Cell Lung CancerKorea, Republic of
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States, Canada, United Kingdom, Australia